Global Alzheimer's Disease Therapeutics and Diagnostics Scope and Market Size
Alzheimer's Disease Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimer's Disease Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Market segment by Application, split into
Drugs Market
Diagnostics Market
Based on regional and country-level analysis, the Alzheimer's Disease Therapeutics and Diagnostics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Alzheimer's Disease Therapeutics and Diagnostics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Biomarkers
1.2.3 Cholinesterase inhibitors
1.2.4 NMDA receptor antagonists
1.2.5 Brain imaging
1.2.6 Blood tests
1.3 Market by Application
1.3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
1.3.2 Drugs Market
1.3.3 Diagnostics Market
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Perspective (2015-2026)
2.2 Global Alzheimer's Disease Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Alzheimer's Disease Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alzheimer's Disease Therapeutics and Diagnostics Historic Market Share by Regions (2015-2020)
2.2.3 Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Market Size
3.1.1 Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Revenue (2015-2020)
3.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Players (2015-2020)
3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Alzheimer's Disease Therapeutics and Diagnostics Revenue
3.4 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alzheimer's Disease Therapeutics and Diagnostics Revenue in 2019
3.5 Key Players Alzheimer's Disease Therapeutics and Diagnostics Area Served
3.6 Key Players Alzheimer's Disease Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Alzheimer's Disease Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Type (2015-2026)
4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Type (2021-2026)
5 Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Application (2015-2026)
5.1 Global Alzheimer's Disease Therapeutics and Diagnostics Historic Market Size by Application (2015-2020)
5.2 Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)
6.2 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)
6.3 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)
6.4 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)
7.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)
7.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)
7.4 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)
8.2 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)
8.3 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)
8.4 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)
9.2 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)
9.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)
9.4 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)
10.2 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)
10.3 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)
10.4 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Namenda
11.1.1 Namenda Company Details
11.1.2 Namenda Business Overview
11.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.1.4 Namenda Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020))
11.1.5 Namenda Recent Development
11.2 Aricept
11.2.1 Aricept Company Details
11.2.2 Aricept Business Overview
11.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.2.4 Aricept Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.2.5 Aricept Recent Development
11.3 Exelon
11.3.1 Exelon Company Details
11.3.2 Exelon Business Overview
11.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.3.4 Exelon Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.3.5 Exelon Recent Development
11.4 Solanezumab
11.4.1 Solanezumab Company Details
11.4.2 Solanezumab Business Overview
11.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.4.4 Solanezumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.4.5 Solanezumab Recent Development
11.5 Gantenerumab
11.5.1 Gantenerumab Company Details
11.5.2 Gantenerumab Business Overview
11.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.5.4 Gantenerumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.5.5 Gantenerumab Recent Development
11.6 Verubecestat
11.6.1 Verubecestat Company Details
11.6.2 Verubecestat Business Overview
11.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.6.4 Verubecestat Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.6.5 Verubecestat Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.7.4 Pfizer Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.7.5 Pfizer Recent Development
11.8 Eisai
11.8.1 Eisai Company Details
11.8.2 Eisai Business Overview
11.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.8.4 Eisai Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.8.5 Eisai Recent Development
11.9 Actavis
11.9.1 Actavis Company Details
11.9.2 Actavis Business Overview
11.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.9.4 Actavis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.9.5 Actavis Recent Development
11.10 Lundbeck
11.10.1 Lundbeck Company Details
11.10.2 Lundbeck Business Overview
11.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Introduction
11.10.4 Lundbeck Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
11.10.5 Lundbeck Recent Development
11.11 Daiichi Sankyo
10.11.1 Daiichi Sankyo Company Details
10.11.2 Daiichi Sankyo Business Overview
10.11.3 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Introduction
10.11.4 Daiichi Sankyo Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
10.11.5 Daiichi Sankyo Recent Development
11.12 Novartis
10.12.1 Novartis Company Details
10.12.2 Novartis Business Overview
10.12.3 Novartis Alzheimer's Disease Therapeutics and Diagnostics Introduction
10.12.4 Novartis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
10.12.5 Novartis Recent Development
11.13 TauRx
10.13.1 TauRx Company Details
10.13.2 TauRx Business Overview
10.13.3 TauRx Alzheimer's Disease Therapeutics and Diagnostics Introduction
10.13.4 TauRx Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
10.13.5 TauRx Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
*If Applicable.